Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
2008 Standout
Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)
2013
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
Effect of Candesartan and Various Inflammatory Markers on Maintenance of Sinus Rhythm After Electrical Cardioversion for Atrial Fibrillation
2007
The paradox of low BNP levels in obesity
2011
Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor Receptor
2009 StandoutNobel
β-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor Stimulation
2002 StandoutNobel
Guidelines for the diagnosis and treatment of chronic heart failure
2001
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
2005
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
2001 Standout
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
2003 Standout
The Failing Heart — An Engine Out of Fuel
2007 Standout
Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure
2014
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
2005
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
2003 Standout
Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension
2010 Standout
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
2009 Standout
β-Arrestin 1 and Gαq/11 Coordinately Activate RhoA and Stress Fiber Formation following Receptor Stimulation
2004 StandoutNobel
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Prevention of Atrial Fibrillation by Renin-Angiotensin System Inhibition
2010
Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure
2006
Is atrial fibrillation an inflammatory disorder?
2005
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
2009 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure
2005 Standout
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
2004
Update on recent clinical trials in congestive heart failure
2000
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
2003 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Regression of Electrocardiographic Left Ventricular Hypertrophy and Decreased Incidence of New-Onset Atrial Fibrillation in Patients With Hypertension
2006
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
2009
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study
2002
Troponin Elevation in Heart Failure
2010
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
2001 Standout
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
2003 Standout
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
2016
Cardiac Resynchronization in Chronic Heart Failure
2002 Standout
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction Delay
2001 Standout
Treatment of Hypertension in Patients 80 Years of Age or Older
2008 Standout
Diabetic foot ulcers
2003 Standout
Rationale for Fixed-Dose Combinations in the Treatment of Hypertension
2002
Heart failure
2005
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors
2002
The STARBRITE Trial: A Randomized, Pilot Study of B-Type Natriuretic Peptide–Guided Therapy in Patients With Advanced Heart Failure
2011
Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
2006
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention
2011
Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials
2009
Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure
2011
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
2005 Standout
Prevalence and Incidence of Arrhythmias and Sudden Death in Heart Failure
2002
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?
2005
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2004 Standout
Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency
2007
Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR‐HF) study: a randomized, placebo‐controlled study of intravenous iron supplementation in patients with and without anaemia
2009
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
2003 Standout
Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure
2013
Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure
2000
N-Terminal Pro–B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure
2009
Structural and Functional Remodeling of the Left Atrium
2008
Biomarkers in Heart Failure
2008 Standout
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
2006
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
2009 Standout
Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure
2002 Standout
New Roles for β-Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors
2006 StandoutNobel
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches
2011
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure
2009
Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a pilot study
2009
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS‐HF)
2010
The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study
2005
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2011
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II
2000
Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure
1999
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
Transcatheter Mitral-Valve Repair in Patients with Heart Failure
2018 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Variable Impact of Combining Fatal and Nonfatal End Points in Heart Failure Trials
2006
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
2000 Standout
Review: Prospects for ARB in the next five years
2001
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Functional antagonism of different G protein-coupled receptor kinases for β-arrestin-mediated angiotensin II receptor signaling
2005 StandoutNobel
Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure
2001 StandoutNobel
Iron-Deficiency Anemia
2015 Standout
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
2006
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
2006
Dermal Neurovascular Dysfunction in Type 2 Diabetes
2001
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
2008
Anemia in Chronic Heart Failure
2006
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
2010 Standout
Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia
2008
Works of Robert Glazer being referenced
Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val‐HeFT
2004
Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo
1996
Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
1999
Pharmacokinetics of Multiple Doses of Valsartan in Patients With Heart Failure
2002
Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT
2006
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure
2004
Dose-response efficacy of valsartan, a new angiotensin II receptor blocker
1999
Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)
2005
Baseline demographics of the Valsartan Heart Failure Trial
2000
Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
2003
Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure
2005
C-Reactive Protein in Heart Failure
2005
Valsartan: Preclinical and Clinical Profile of an Antihypertensive Angiotensin‐II Antagonist
1995
Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure
2003